Osteoprotective medication in the era of novel agents: a European perspective on values, risks and future solutions

Haematologica. 2018 May;103(5):755-758. doi: 10.3324/haematol.2018.188516.

Monika Engelhardt^{1

2}, Georg W Herget³, Giulia Graziani^{4

2}, Gabriele Ihorst⁵, Heike Reinhardt^{4

2}, Stefanie Ajayi^{4

2}, Stefan Knop⁶, Ralph Wasch^{4

2}

¹ Department of Medicine I, Hematology, Oncology & Stem Cell Transplantation, Medical Center, University of Freiburg, Germany monika.engelhardt@uniklinik-freiburg.de.
² Comprehensive Cancer Center Freiburg (CCCF), Medical Center, University of Freiburg, Germany.
³ Department of Orthopedics and Trauma Surgery, Medical Center, University of Freiburg, Germany.
⁴ Department of Medicine I, Hematology, Oncology & Stem Cell Transplantation, Medical Center, University of Freiburg, Germany.
⁵ Clinical Trials Unit, Medical Center, University of Freiburg, Germany.
⁶ Hematology, Oncology, Gastroenterology, University of Würzburg, Germany.

No abstract available

MeSH terms